Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight

GlobeNewswire Inc. • Jan 13, 2026 1:00pm (New York) •By Delveinsight

Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight

The systemic lupus erythematosus (SLE) market is projected to grow at a CAGR of 9.4% from 2025-2034, driven by rising disease prevalence, increased diagnostic awareness, and a robust pipeline of targeted therapies. The US market was valued at USD 2.8 billion in 2024 with approximately 529K diagnosed cases. Currently, only two FDA-approved therapies exist (BENLYSTA and SAPHNELO), but several promising drugs in mid-to-late stage development are expected to reshape the treatment landscape and address significant unmet medical needs.

← Back to news Read Original Article

Insights

COMP neutral

Merger with Anywhere Real Estate where current shareholders will own 78% of combined company

JNJ positive

Developing nipocalimab, an investigational FcRn inhibitor in Phase 3 development with favorable Phase 2b JASMINE trial results reported in January 2026, positioning the company well in the growing SLE market.

Keywords

#systemic lupus erythematosus #SLE market growth #biologics #monoclonal antibodies #JAK inhibitors #autoimmune disease #clinical trials #FDA approval #drug pipeline

Tickers

JNJ GSK AZN NVS BIIB VTRS BMY CELGr ABBV

← Prev: Wayfair Partners With Google AI To Bring Smarter Online Buying

Next: Equinor Secures 35 New Norwegian Offshore Licenses →